FDA Publishes Draft Guidance On Psychedelic Drug Research
By Mike Curley
The U.S. Food and Drug Administration on Friday published a new draft guidance highlighting considerations researchers should take into account while investigating the use of psychedelic drugs like psilocybin for treatment of medical conditions like depression and post-traumatic stress disorder.